Viridian Therapeutics Files 8-K on Financials
Ticker: VRDN · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1590750
Sentiment: neutral
Topics: financial-reporting, corporate-actions
TL;DR
Viridian Therapeutics (VRDN) filed an 8-K on Aug 6, 2025, detailing financial results and operations.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
Why It Matters
This filing provides an update on Viridian Therapeutics' financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate material changes or risks.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- August 6, 2025 (date) — Date of earliest event reported
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Viridian Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 6, 2025.
What were Viridian Therapeutics, Inc.'s previous names?
Viridian Therapeutics, Inc. was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
In which state is Viridian Therapeutics, Inc. incorporated?
Viridian Therapeutics, Inc. is incorporated in Delaware.
What is the SIC code for Viridian Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Viridian Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Viridian Therapeutics, Inc.\DE (VRDN).